Sermorelin Purity: 909 Lab Tests Across 373 Identified Manufacturers
85 studies on Sermorelin curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Bottom line: TitrateLab currently tracks 909 published third-party lab tests of Sermorelin across 373 identified manufacturers. Among reports with a positive numeric purity result, the average is 99.21%. Within this published corpus, 3 positive purity results were below 90%, and 28 reports showed measured quantity more than 10% below the label claim. These are batch-level observations, not guarantees of product identity, safety, or vendor quality.
Sermorelin average prices
As of 2026-09-03, vendor-blind retail asking-price averages for the US delivery market, calculated from the same in-stock exact-strength cells as the Peptide Price Index. Shipping is excluded.
| Strength | Average / vial | Observed range / vial | Average / mg | Coverage |
|---|---|---|---|---|
| 2 mg | $6.50 | $6.50–$6.50 | $3.25 | 1 source · 1 offer |
| 5 mg | $9.30 | $5.50–$11.50 | $1.86 | 5 sources · 5 offers |
| 10 mg | $15.75 | $14.50–$17.00 | $1.57 | 2 sources · 2 offers |
Asking prices are not manufacturing cost and do not establish product equivalence, quality, safety, or legality. The refresh date is the catalog build date; individual source observation dates are not available in this snapshot. View full price methodology →
We tested 909 Sermorelin batches across 373 identified manufacturers
Independent certificate-of-analysis evidence from third-party labs — the data behind the studies. Updated as new COAs are verified. Read the full grey-market analysis →
Within that total, 192 batches have unresolved manufacturer identity. They remain in corpus-level lab evidence and are excluded from named-manufacturer rankings.
Top 3 vendor evidence profiles for Sermorelin
Eligible vendors have at least 2 deduplicated tests and 2 classifiable identity observations. Rank uses the 95% lower confidence bound on clean identity results; mean positive purity and test count break ties. Missing measurements are not passes. Exact-zero/not-detected and explicit wrong-compound markers count once per adverse certificate. This describes tested batches, not every product or shipment, and is not an endorsement.
| Rank | Manufacturer | Tests | Avg positive purity | Identity adverse results | |
|---|---|---|---|---|---|
| #1 | 26 | 99.24% | 0 of 21 (0.0%) 0 0% / not detected · 0 wrong compound · 5 unclassified | Reveal with Pro → | |
| #2 | 14 | 99.03% | 0 of 13 (0.0%) 0 0% / not detected · 0 wrong compound · 1 unclassified | Reveal with Pro → | |
| #3 | 13 | 99.4% | 0 of 12 (0.0%) 0 0% / not detected · 0 wrong compound · 1 unclassified | Reveal with Pro → |
Manufacturer identities are included with Pro. Batch counts and lab measurements remain visible.
Recent certificates: #100613 (99.39%) · #100201 (99.23%) · #101011 (99.72%) · #99645 (99.25%) · #100311 (99.14%) · #100502 (99.41%)
Sermorelin studies and clinical research
-
Long-Running Endocrine Disease Study Terminated Without Public Results
The termination of this long-running study highlights the significant challenges inherent in conducting extensive, multi-year clinical research, particularly in broad observational contexts like endocrine diseases. Wh…
-
GHRH Antagonist Explored for Acromegaly: Unraveling GH Hypersecretion Mechanisms
Understanding the precise role of GHRH (a hormone that stimulates GH release) in acromegaly is crucial for developing more targeted therapies. If endogenous GHRH significantly contributes to GH hypersecretion, then GH…
-
GHRH Explored as Treatment for Age-Related Sleep Disturbances
If GHRH were found to be effective, this research could pave the way for a novel therapeutic strategy to address age-related sleep disturbances, a widespread issue affecting millions. Successfully augmenting the GH-IG…
-
Terminated Study Explored GHRH for Muscle, Bone, and Fat in Elderly
The premature termination of this study means a potential avenue for addressing age-related decline in muscle, bone, and fat health through GHRH remains unexplored by this particular trial. If successful, GHRH could h…
-
GHRH Therapy Explored for Improving Heart Function in Congestive Heart Failure
These findings suggest that GHRH therapy could represent a novel therapeutic strategy for improving cardiac function and quality of life in older adults with congestive heart failure and reduced growth hormone effect.…
-
Long vs. Short Clomid Protocol for IVF in Diminished Ovarian Reserve
This research is critical for optimizing IVF protocols for a challenging patient population with diminished ovarian reserve, who often have lower success rates with conventional treatments. If the long Clomid protocol…
-
Tesamorelin Significantly Reduces Liver Fat in Adults with MASLD
This study provides compelling evidence that tesamorelin could be a highly effective pharmacological intervention for MASLD, addressing a critical unmet medical need. The significant reduction in liver fat observed su…
-
Terminated Study Explored GHRH's Potential for Muscle, Bone, and Fat in Elderly
The premature termination of this study means a significant opportunity was missed to explore a potential therapeutic avenue for age-related decline. Given the widespread impact of low GH levels on muscle mass, bone d…
-
Tesamorelin's Impact on Body Fat in HIV Lipodystrophy Patients
-
Study Planned to Investigate Variability in Growth Hormone and IGF-1 Assays
The intent behind this study highlights a critical challenge in endocrinology: the potential for significant inter-assay variability to compromise the accurate diagnosis and management of Growth Hormone (GH) disorders…
-
Investigating Tesamorelin's Potential to Improve Sleep Apnea in Lipodystrophy
The intent behind this withdrawn study highlights a critical unmet need: finding effective treatments for sleep-disordered breathing in patients with lipodystrophy. If Tesamorelin could demonstrably improve sleep apne…
-
Tesamorelin Shows Promise for Reducing Liver Fat in Obese NAFLD Patients
These findings, if confirmed upon publication, would establish tesamorelin as a promising therapeutic option for NAFLD in obese individuals, addressing a critical unmet medical need. Given the high prevalence of NAFLD…
-
Growth Hormone Releasing Hormone Explored for Abdominal Fat Reduction in Obesity
Targeting growth hormone pathways with GHRH offers a promising therapeutic strategy for managing abdominal obesity and its associated metabolic risks. If successful, this approach could provide a novel, physiological …
-
Sex Differences in Growth Hormone Response to GHRH Stimulation Testing
Understanding the sexually dimorphic nature of GH responses to GHRH could profoundly impact the diagnosis and management of Growth Hormone Deficiency. If confirmed, these findings could lead to the development of sex-…
-
GHRH Explored for Cognitive Enhancement in Aging and Mild Cognitive Impairment
-
Adult Growth Hormone Deficiency Linked to Increased Cardiovascular Risk
-
Tesamorelin's Drug Profile and Safety Explored in HIV Patients
This foundational Phase 1 study is critical because it provides essential data on how Tesamorelin behaves in HIV positive patients, a population with unique metabolic considerations. The successful characterization of…
-
Tesamorelin Plus Exercise to Boost Physical Function in HIV Patients
The potential for Tesamorelin to augment exercise benefits in HIV-positive individuals is highly significant. If successful, this intervention could offer a novel and more effective strategy to combat frailty and phys…
-
Tesamorelin's Short-Term Effects on Growth Hormone and Insulin in Healthy Men
Understanding Tesamorelin's short-term effects in healthy individuals is crucial for broadening its potential therapeutic applications beyond HIV-associated lipodystrophy. If Tesamorelin can safely enhance GH secretio…
-
TH9507 Safety and Efficacy Explored for Type 2 Diabetes Management
The investigation into TH9507, a growth hormone-releasing factor (GRF) analogue, represents an important step in exploring novel therapeutic strategies for Type 2 Diabetes. GRF plays a role in metabolic regulation, an…
-
Tesamorelin Investigated for Liver Fat and Histology in HIV Patients
-
GHRH Analogue Explored for Abdominal Fat and Heart Inflammation
This study, had it been completed, could have provided crucial evidence for a novel therapeutic strategy to mitigate cardiovascular risk in individuals with abdominal obesity. By demonstrating a direct link between GH…
-
Long-Term Safety and Effectiveness of Somatropin in Children
-
Growth Hormone Therapy Explored for Lung Function and Quality of Life in Children with GHD.
-
Growth Hormone Effects on Brain Secretion and Glucose in HIV Patients
Understanding how growth hormone and growth hormone-releasing hormone impact GH secretion and glucose metabolism in HIV-infected patients is profoundly important for managing HIV lipodystrophy and its associated metab…
-
GHRH + Arginine Test Validated for Adult Growth Hormone Deficiency Diagnosis
If the GHRH + Arginine test proves to have high specificity and sensitivity comparable to the ITT, it could represent a significant advancement in diagnosing AGHD. The ITT carries inherent risks due to induced hypogly…
-
Terminated Study Explored Niacin's Impact on Growth Hormone in Obese Children
The termination of this study represents a missed opportunity to gain crucial insights into the complex interplay between free fatty acids, obesity, and growth hormone secretion in a vulnerable pediatric population. H…
-
Withdrawn Study Explored GHRH Analog for TBI-Related Insomnia in Service Members
The withdrawal of this study highlights a persistent gap in research for effective treatments for TBI-related insomnia, a condition that significantly impacts the quality of life for service members and veterans. Had …
-
Tesamorelin Reduces Visceral Fat and Improves Heart Health in HIV Lipodystrophy
This research highlights tesamorelin's potential as a targeted therapeutic option for managing HIV lipodystrophy, offering more than just cosmetic benefits. The significant reduction in visceral fat, coupled with impr…
-
Estrogen Receptor Blockade Explored for Growth Hormone Regulation in Older Adults
-
VRS-317 Phase 1 Study Explores Long-Acting Growth Hormone Deficiency Treatment
This Phase 1 study is crucial for establishing the foundational safety and preliminary efficacy signals for VRS-317, a potential long-acting treatment for Growth Hormone Deficiency. If successful in maintaining IGF-I …
-
Oral AEZS-130 Explored as Safer Growth Hormone Deficiency Diagnostic Test
The successful development of an oral growth hormone secretagogue like AEZS-130 for diagnostic purposes would represent a significant advancement in the management of Adult Growth Hormone Deficiency (AGHD). Such a tes…
-
TH9507: A Growth Hormone Releasing Factor Analog for HIV-Associated Lipodystrophy
The potential of TH9507 to selectively reduce visceral adipose tissue (VAT) in HIV patients with lipodystrophy is highly significant, as this fat accumulation is strongly linked to serious metabolic complications like…
-
DHEA vs. Growth Hormone for Poor Ovarian Response in ICSI
For women struggling with poor ovarian response (POR), finding effective pre-treatment strategies is paramount to improving the success rates of IVF/ICSI and alleviating the significant emotional and financial burden …
-
GHRH Explored for Improving Cognition in Individuals with Mild Cognitive Impairment
If Growth Hormone Releasing Hormone (GHRH) were to demonstrate positive effects on cognitive function in Mild Cognitive Impairment (MCI), it would offer a novel and promising therapeutic strategy for a condition with …
-
Synergistic Effects of Growth Hormone-Releasing Hormones and Peptides in Men
This research provides crucial insights into the potentiation of GH secretion when GHRH and GHRPs are co-administered, suggesting a more efficient way to stimulate endogenous GH release. The observed synergy could all…
-
GHRH Antagonists Show Promise Against Aggressive Triple-Negative Breast Cancer
These findings are highly significant as they identify the GHRH receptor as a novel and promising therapeutic target for triple-negative breast cancer, a disease with limited treatment options. The potent anti-prolife…
-
GHRH Antagonist JMR-132 Halts Cancer Cell Growth by Activating p21/waf1
This research elucidates a critical molecular pathway by which GHRH antagonists like JMR-132 exert their anti-cancer effects, specifically highlighting the essential role of p21/waf1 (a protein that halts cell divisio…
-
GHRH Antagonist Shows Broad Efficacy Against Estrogen Receptor Positive and Negative Breast Cancer
This study highlights a novel therapeutic approach for breast cancer treatment by targeting the GHRH pathway, showing efficacy across both ER+ and ER- subtypes. The ability of MZ-4-71 to inhibit the growth of ER- brea…
-
GHRH Antagonists Exhibit Antioxidant Effects in Prostate Cancer Cells
-
GHRH(1-29)NH2 Stimulates Growth and Secretion in Human Lung Neuroendocrine Tumor Cells
These findings are significant as they identify GHRH as a trophic hormone for bronchial neuroendocrine tumors, meaning it actively promotes their growth and activity. This discovery suggests that GHRH receptors could …
-
GHRH Antagonist Halts Ovarian Cancer Cell Growth via EGFR-Akt Pathway
This study provides compelling evidence that GHRH antagonists possess significant antiproliferative and pro-apoptotic effects on ovarian cancer cells by targeting the EGFR-Akt signaling pathway. This discovery highlig…
-
Growth Hormone Releasing Hormone Boosts Nitric Oxide Synthase Production
This discovery is significant because it uncovers a novel mechanism by which Growth Hormone Releasing Hormone (GHRH) may exert its diverse biological effects, independent of growth hormone (GH) release. By inducing ni…
-
GHRH Antagonist Extends Lifespan and Reverses Aging Markers in Mice
This study provides compelling evidence that targeting the GHRH/GH axis with an antagonist can significantly impact multiple facets of aging, including longevity, oxidative stress, and telomerase activity. The observe…
-
GH-RH Antagonist Improves Cognition and Reduces Anxiety in Mouse Brains
This study provides compelling evidence that GH-RH antagonism can profoundly influence brain function, leading to significant improvements in both cognitive abilities and emotional regulation. These findings suggest a…
-
GHRH Antagonists Inhibit Prostate Cancer by Modulating p53 Tumor Suppressor
This research highlights the therapeutic potential of GHRH antagonists as a novel and targeted approach for treating prostate cancer. By modulating key cellular pathways, specifically restoring the function of the p53…
-
GHRH Antagonists Show Strong Potential Against Human Ovarian Cancer Growth
Given the aggressive nature and poor prognosis of advanced ovarian cancer, identifying new therapeutic avenues is paramount. This research highlights GHRH antagonists as a highly promising novel therapeutic strategy f…
-
GHRH Receptor Activation Promotes Significant Heart Repair After Heart Attack
-
GHRH Inhibition Worsens Acetaminophen-Induced Liver Damage in Mice
This research highlights the critical protective role of GHRH and the downstream GH/IGF-I axis in mitigating acute liver injury caused by acetaminophen. The findings suggest that maintaining or enhancing GHRH signalin…
-
GHRH Antagonist Impairs Learning by Modulating Brain Neurotransmitters
This study highlights the complex role of GHRH signaling in cognitive function and its intricate interplay with various neurotransmitter systems. Understanding these pathways could open new avenues for treating cognit…
Research tools
Free, no account — handy when you're working with Sermorelin.
